159 related articles for article (PubMed ID: 24625884)
1. The influence of prostate volume on cancer detection in the Chinese population.
Wu YS; Na R; Xu JF; Bai PD; Jiang HW; Ding Q
Asian J Androl; 2014; 16(3):482-6. PubMed ID: 24625884
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011.
Na R; Jiang H; Kim ST; Wu Y; Tong S; Zhang L; Xu J; Sun Y; Ding Q
PLoS One; 2012; 7(11):e49914. PubMed ID: 23189170
[TBL] [Abstract][Full Text] [Related]
3. Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population.
Na R; Wu Y; Xu J; Jiang H; Ding Q
PLoS One; 2013; 8(6):e67585. PubMed ID: 23825670
[TBL] [Abstract][Full Text] [Related]
4. Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective.
Kash DP; Lal M; Hashmi AH; Mubarak M
Asian Pac J Cancer Prev; 2014; 15(7):3087-91. PubMed ID: 24815452
[TBL] [Abstract][Full Text] [Related]
5. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.
Chiu PK; Roobol MJ; Teoh JY; Lee WM; Yip SY; Hou SM; Bangma CH; Ng CF
Int Urol Nephrol; 2016 Oct; 48(10):1631-7. PubMed ID: 27349564
[TBL] [Abstract][Full Text] [Related]
6. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
8. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
[TBL] [Abstract][Full Text] [Related]
9. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
10. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
[TBL] [Abstract][Full Text] [Related]
11. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia.
Mao Q; Zheng X; Jia X; Wang Y; Qin J; Yang K; Bai Y; Xie L
Int Urol Nephrol; 2009 Dec; 41(4):761-6. PubMed ID: 19224388
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population?
Teoh JY; Yuen SK; Tsu JH; Wong CK; Ho BSh; Ng AT; Ma WK; Ho KL; Yiu MK
Asian J Androl; 2015; 17(5):821-5. PubMed ID: 25652619
[TBL] [Abstract][Full Text] [Related]
13. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
Hugosson J; Aus G; Bergdahl S; Fernlund P; Frösing R; Lodding P; Pihl CG; Lilja H
BJU Int; 2003 Dec; 92 Suppl 2():39-43. PubMed ID: 14983953
[TBL] [Abstract][Full Text] [Related]
14. Prostate volume as an independent predictor of prostate cancer in men with PSA of 10-50 ng ml(-1).
Tang P; Jin XL; Uhlman M; Lin YR; Deng XR; Wang B; Xie KJ
Asian J Androl; 2013 May; 15(3):409-12. PubMed ID: 23564045
[TBL] [Abstract][Full Text] [Related]
15. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
[TBL] [Abstract][Full Text] [Related]
16. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.
Lazzeri M; Haese A; de la Taille A; Palou Redorta J; McNicholas T; Lughezzani G; Scattoni V; Bini V; Freschi M; Sussman A; Ghaleh B; Le Corvoisier P; Alberola Bou J; Esquena Fernández S; Graefen M; Guazzoni G
Eur Urol; 2013 Jun; 63(6):986-94. PubMed ID: 23375961
[TBL] [Abstract][Full Text] [Related]
17. [Establishment of a scoring system for predicting the positive rate of prostatic biopsy for prostate cancer].
Chen JG; Chen XF; Gu DH; Lu M; Zheng B; Zhang B; Pan B; Zhu H; Pan XD; Xu B; Qian L
Zhonghua Nan Ke Xue; 2015 Jan; 21(1):53-6. PubMed ID: 25707141
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
[TBL] [Abstract][Full Text] [Related]
19. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
20. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
